| Authors: |
Barceló C; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Sisó P; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Maiques O; Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., García-Mulero S; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain., Sanz-Pamplona R; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain., Navaridas R; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Megino C; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Felip I; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Urdanibia I; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Eritja N; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Soria X; Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain., Piulats JM; Department of Medical Oncology, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Penin RM; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, l'Hospitalet de Llobregat, Barcelona, Spain., Dolcet X; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain., Matías-Guiu X; Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, l'Hospitalet de Llobregat, Barcelona, Spain; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Martí RM; Department of Dermatology, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, Lleida, Spain; Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Electronic address: marti@medicina.udl.cat., Macià A; Oncologic Pathology Group, University of Lleida, IRBLleida, Lleida, Spain. Electronic address: amacia@irblleida.cat. |
